This Was A 'Profound Victory' For Herbalife
Following news of Herbalife Ltd. (NYSE: HLF)'s deal with the FTC, Pivotal Research Group’s Timothy S. Ramey maintained a Buy rating and price target of $90, commenting that the deal represents a “profound victory” for the company. According to the deal, Herbalife has agreed to pay a $200 million fine to the FTC and $3 million to the Illinois Attorney General.
“The company will adopt a two-tier membership structure – a structure HLF floated in the Spring of 2013 as a possibility,” Ramey wrote.
The company would need to show that 80 percent of its product sales are to legitimate end users. Herbalife uses an Oracle enterprise system, which allows tremendous visibility. The FTC changes are applicable only in the US, which accounts for 20 percent of Herbalife sales, Ramey pointed out.
“This deal is consistent with our long-held view that while the company has had certain historic weaknesses in its compliance and oversight, it is a legal and ethical business model with the best-in-industry compliance function today. This is a total victory for Herbalife shareholders and a total defeat for the short camp,” the analyst commented.
The FTC deal effectively gives an “all-clear” for Herbalife as well as USANA Health Sciences, Inc. (NYSE: USNA) [Rated: Buy, PT: $160] and Nu Skin Enterprises, Inc. (NYSE: NUS) [Rated: Buy, PT: $60]. Ramey expects the stock to “re-price rather rapidly to the $80-$100 level.”
Did you like this article? Could it have been improved? Please email feedback@benzinga.com to let us know!
Latest Ratings for HLF
Date | Firm | Action | From | To |
---|---|---|---|---|
Nov 2021 | RBC Capital | Maintains | Sector Perform | |
Sep 2021 | Citigroup | Maintains | Buy | |
Aug 2021 | RBC Capital | Maintains | Sector Perform |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Pivotal Research GroupAnalyst Color Long Ideas News Reiteration Legal Analyst Ratings Trading Ideas Best of Benzinga